Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs

Fineline Cube Feb 12, 2026
Company Deals

Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Fineline Cube Feb 12, 2026
Company Drug

Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer

Fineline Cube Feb 12, 2026
Company Deals

Hengrui Pharmaceuticals Strikes Deal with Hercules CM Newco to Supply GLP-1 Products for Global Markets

Fineline Cube May 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has entered into...

Company Drug

Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer

Fineline Cube May 16, 2024

China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...

Policy / Regulatory

Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment

Fineline Cube May 16, 2024

The US House Committee on Oversight and Accountability has completed the markup process for amendments...

Company Deals

Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support

Fineline Cube May 16, 2024

Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...

Company Deals

AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation

Fineline Cube May 16, 2024

AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure...

Company Deals

Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO

Fineline Cube May 16, 2024

Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...

Company Medical Device

Lifetech Scientific’s IBS Stent Demonstrates Non-Inferiority in Phase II Trial

Fineline Cube May 16, 2024

Lifetech Scientific Corporation (HKG: 1302), a biopharmaceutical company based in China, has announced the completion...

Company Drug

Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial

Fineline Cube May 16, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors

Fineline Cube May 16, 2024

China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...

Company Deals Medical Device

GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment

Fineline Cube May 16, 2024

GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent...

Company Deals Medical Device

Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics

Fineline Cube May 16, 2024

Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+...

Company Deals

Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets

Fineline Cube May 16, 2024

Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...

Company Deals Hospital

Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China

Fineline Cube May 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...

Company Drug

Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch

Fineline Cube May 15, 2024

Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...

Company Deals

Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round

Fineline Cube May 15, 2024

China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...

Company Policy / Regulatory

US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports

Fineline Cube May 15, 2024

The US Office of the Trade Representative (USTR) has announced a series of stringent new...

Company

Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation

Fineline Cube May 15, 2024

Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...

Company Drug

Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod

Fineline Cube May 15, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China

Fineline Cube May 15, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...

Company Drug

Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy

Fineline Cube May 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Posts pagination

1 … 318 319 320 … 624

Recent updates

  • Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
  • Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
  • Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
  • MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
  • Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.